A detailed history of Clearstead Advisors, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Clearstead Advisors, LLC holds 429 shares of HALO stock, worth $20,231. This represents 0.0% of its overall portfolio holdings.

Number of Shares
429
Previous 429 -0.0%
Holding current value
$20,231
Previous $22,000 9.09%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$37.81 - $52.4 $9,717 - $13,466
257 Added 149.42%
429 $22,000
Q1 2024

May 14, 2024

BUY
$33.68 - $41.95 $1,650 - $2,055
49 Added 39.84%
172 $6,000
Q4 2023

Feb 12, 2024

BUY
$33.32 - $42.1 $1,499 - $1,894
45 Added 57.69%
123 $4,000
Q1 2023

May 09, 2023

BUY
$32.86 - $55.7 $854 - $1,448
26 Added 50.0%
78 $2,000
Q4 2022

Feb 14, 2023

BUY
$40.06 - $59.44 $2,083 - $3,090
52 New
52 $2,000
Q4 2021

Feb 14, 2022

SELL
$31.82 - $40.75 $17,691 - $22,657
-556 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$38.47 - $46.42 $21,389 - $25,809
556 New
556 $23,000

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $6.57B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Clearstead Advisors, LLC Portfolio

Follow Clearstead Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Clearstead Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Clearstead Advisors, LLC with notifications on news.